News|Articles|October 5, 2006

Court Refuses to Alter Compounding Decision

Missouri City, TX (Oct. 3)-The US District Court for the Western District of Texas denied the Department of Justice?s motion to alter its Aug. 30 decision that the US Food and Drug Administration does not have the ability to regulate drug compounding.

Missouri City, TX (Oct. 3)-The US District Court for the Western District of Texas denied the Department of Justice’s motion to alter its Aug. 30 decision that the US Food and Drug Administration does not have the ability to regulate drug compounding.

The court ruled in Medical Center Pharmacy, et al. v. Gonzalez that compounded pharmaceuticals do not fit FDA’s definition of new drugs and that such products are therefore exempt from the new drug application process. The court further held that the agency could not block pharmacists from creating individually tailored drugs with bulk ingredients.

 


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.